Quinazoline compounds as modulators of Ras signaling
US11318137B2 · kind B2 · utility
0Cited by
0References
41Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2017 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | May 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g., Ras-associated autoimmune leukoproliferative disorder, or certain types of mitochondrial dysfunction) in a subject, for example a mammal or a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.